Tirzepatide for Sleep Apnea
- Tirzepatide (Zepbound) was approved for treating sleep apnea in adults with obesity, per a recent report. (ajmc.com) - The approval was based on the SURMOUNT‑OSA trial, which showed patients had fewer breathing disruptions on treatment. (ajmc.com) - The label specifically targets adults with obesity and sleep apnea, expanding tirzepatide beyond purely weight‑loss indications. (ajmc.com)
Sleep apnea is a disorder in which the throat closes again and again during sleep, cutting off breathing; on December 20, 2024, the Food and Drug Administration approved Zepbound as the first drug for some adults with that condition. (fda.gov) The approval covers adults with obesity and moderate to severe obstructive sleep apnea, and the label says the drug should be used with a reduced-calorie diet and more physical activity. (fda.gov) Doctors usually measure sleep apnea with the apnea-hypopnea index, or AHI, which counts breathing disruptions per hour of sleep. In the two SURMOUNT-OSA trials, Zepbound cut that index by 25.3 and 29.3 events per hour after 52 weeks, versus 5.3 and 5.5 with placebo. (nejm.org) The studies enrolled 469 adults with obesity and moderate to severe obstructive sleep apnea. One trial included people who could not or would not use positive airway pressure, while the other included people already using that air-pressure treatment. (nejm.org) Positive airway pressure, or PAP, is the standard treatment that keeps the airway open by blowing air through a mask during sleep. The American Academy of Sleep Medicine said Zepbound gives patients another option, but it did not replace the need for evaluation and treatment at a sleep center. (aasm.org) The Food and Drug Administration said the improvement in breathing disruptions was likely related to body-weight reduction with tirzepatide. In the trials, patients on the drug also lost substantially more weight than those on placebo. (fda.gov; nejm.org) Tirzepatide works by mimicking two gut hormones, GLP-1 and GIP, that help regulate appetite and blood sugar. Zepbound had already been sold in the United States since November 2023 for chronic weight management before the sleep-apnea indication was added. (fda.gov; accessdata.fda.gov) The label also carries the drug’s usual warnings and side effects, including nausea, diarrhea, vomiting, constipation, stomach pain, injection-site reactions, fatigue, allergic reactions, belching, hair loss, and gastroesophageal reflux disease. The Food and Drug Administration says tirzepatide should not be used in patients with a personal or family history of medullary thyroid cancer or Multiple Endocrine Neoplasia syndrome type 2. (accessdata.fda.gov) That leaves sleep doctors with a new kind of prescription: not a machine that pushes air, but a weekly injection aimed at the obesity that often helps drive the airway shut at night. (aasm.org; fda.gov)
